Organon Obtains License for Merck's Novel Oral Contraceptive

Akzo Nobel's human healthcare business, Organon, has been granted worldwide development and marketing rights by Merck KGaA affiliate Laboratoire Théramex for its novel oral contraceptive EMM 310066. Already successful in Phase II clinical trials, EMM 310066 has been designed to address unmet needs in the oral contraceptive market. By obtaining the license from Théramex, Organon -- a world leader in both oral and non-oral contraceptives -- is confirming its commitment to bring innovative birth control methods to millions of women all over the world, whether they prefer the pill or an alternative method.

()a href="http://www.medadnews.com/News/index.cfm?articleid=244158" target="_blank">PharmaLive